Ashley Kalinauskas

Ashley is the founder and CEO of Torigen Pharmaceuticals—a startup that resulted from her graduate thesis project at the University of Notre Dame. Ashley graduated from the University of Connecticut in 2012 with an undergraduate degree in Pathobiology and went on to complete her Masters at the University of Notre Dame, graduating in 2013. Torigen and its first product, an experimental autologous cancer vaccine, are based upon the research of former University of Notre Dame professor Dr Mark Suckow.